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Abstract: Two decades of investigations have failed to unequivocally clarify the   functions and 
the molecular nature of imidazoline-2 receptors (I2R). However, there is robust pharmacological 
evidence for the functional modulation of monoamino oxidase (MAO) and other important enzyme 
activities by I2 site ligands. Some compounds of this class proved to be active experimental 
tools in preventing both experimental pain and opioid tolerance and dependence.   Unfortunately, 
even though these compounds bind with high potency to central I2 sites, they fail to represent 
a valid clinical opportunity due to their pharmacokinetic, selectivity or side-effects profile. 
This paper presents the preclinical profile of a novel I2 ligand   (2-phenyl-6-(1H-imidazol-1yl)
quinazoline; [CR4056]) that selectively inhibits the activity of human recombinant MAO-A in 
a concentration-dependent manner. A sub-chronic four day oral treatment of CR4056 increased 
norepinephrine (NE) tissue levels both in the rat cerebral cortex (63.1% ± 4.2%; P , 0.05) and 
lumbar spinal cord (51.3% ± 6.7%; P , 0.05). In the complete Freund’s adjuvant (CFA) rat 
model of inflammatory pain, CR4056 was found to be orally active (ED50 = 5.8 mg/kg, by 
mouth [p.o.]). In the acute capsaicin model, CR4056 completely blocked mechanical hyperalgesia 
in the injured hind paw (ED50 = 4.1 mg/kg, p.o.; ED100 = 17.9 mg/kg, p.o.). This effect was 
dose-dependently antagonized by the non-selective imidazoline I2/α2 antagonist idazoxan. In rat 
models of neuropathic pain, oral administration of CR4056 significantly attenuated mechanical 
hyperalgesia and allodynia. In summary, the present study suggests a novel pharmacological 
opportunity for inflammatory and/or neuropathic pain treatment based on selective interaction 
with central imidazoline-2 receptors.
Keywords: imidazoline-2 receptors, hyperalgesia, allodynia, inflammatory pain, neu-
ropathic pain, CR4056
Introduction
Imidazoline binding sites, also known as imidazoline receptors (IRs), are widely 
  distributed in mammalian cells of the central (CNS) and peripheral (PNS) nervous 
systems, liver, kidney and heart.1 To date, three subtypes of such proteins have been pro-
posed (I1, I2, I3). However, only in the case of the I1 subtype was a complete molecular 
characterization achieved. This protein is also referred to as IRAS (imidazoline receptor 
antisera-selected protein)2 and is involved in clonidine-like hypotensive activity.3
Conversely, imidazoline-2 binding sites (I2Rs) are still orphan proteins from a 
molecular point of view, although there is a great deal of experimental evidence related 
to functional modulations by I2R ligands of monoamino-oxidase (MAO) activity 
through their interaction with accessory sites present on discrete populations of MAO 
enzymes.4–7 Other purported activities of I2R ligands are related to the modulation of Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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brain creatine kinase (B-CK)8 and semicarbazide-sensitive 
amino-oxidase (SSAO).9 The physiological relevance of 
these molecular targets may suffice to explain the putative 
involvement of I2R in various diseases10–12 including neuro-
pathic and inflammatory pain.13–16
A number of experimental studies have evaluated the 
interaction between I2R ligands and the opioid system. 
Agmatine, the putative endogenous agonist of imidazoline 
receptors,17 and 2-(2-benzofuranyl)-2-imidazoline (2-BFI), a 
potent and selective I2 ligand,18 have been shown to modulate 
the analgesic effect of morphine in rodents and block the 
development of tolerance to morphine. Ruiz-Durantez et al18 
reported an important cross-talk between I2R ligands and the 
opioid system in the locus coeruleus. Since the descending 
noradrenergic pathway originates in the locus coeruleus and 
extends to the dorsal horn of the spinal cord, such interaction 
could have significant relevance in controlling the central 
sensitization from higher centres to spinal nociceptors. These 
results suggest that compounds of this class, being able to 
cross the blood–brain barrier efficiently, may directly control 
the descending pain pathway, and attenuate the development 
of opioid tolerance and dependence. This could be useful in 
the treatment of chronic and neuropathic pain.
Neuropathic pain is a chronic pain condition often refrac-
tory to multiple treatment modalities including   opioids and 
non-steroidal anti-inflammatory drugs (NSAIDs). Thus, 
current treatment options in neuropathic pain conditions 
are limited to some tricyclic antidepressants (TCAs), anti-
convulsants and systemic local anesthetics. Unfortunately, 
clinical data demonstrate that these drugs usually provide 
either a limited efficacy or low levels of compliance due to 
their side effect profile.19,20
In the present study, we characterized the preclinical 
pharmacological effects of a novel I2R ligand (laboratory 
code CR4056), and tested the hypothesis that this   compound 
induces anti-nociceptive effects in rat models of experi-
mental pain.
Material and methods
Animals
Male Wistar rats (Harlan, Bresso, Italy) weighing 200–300 g 
were used for all experiments. Animals were housed in plas-
tic cages, with free access to standard laboratory food and 
water, under controlled conditions of lighting, humidity, and 
temperature. All experiments were in compliance with the 
European Community Council Directive of 24 November 
1986 (86/609 EEC) for the Care and Use of Laboratory 
Animals.
Pharmacological selectivity assays
The activity of CR4056 was first evaluated in vitro in 
screening assays to assess the pharmacological selectivity 
relative to cell-surface receptors, ion channels, transport sites 
and enzymes by the use of standardized assay protocols as 
described in Table S1 (supplementary data). The following 
additional tests were carried out in order to further investigate 
the results of aforementioned in vitro screening assays.
Binding to imidazoline I2 receptors
Whole brains minus cerebellum from male Wistar rats were 
homogenized in buffered sucrose and centrifuged at 1000 × g 
for 10 minutes at 4°C. Supernatants were pooled, centrifuged 
at 32000 × g for 20 minutes at 4°C and the pellets, suspended 
in assay buffer (50 mM Tris-HCl, 1 mM MgCl2, pH 7.4 at 
4°C), were washed three times by repeated centrifugation as 
above, and then stored at −80°C until use. Prior to radioligand 
binding studies, membrane pellets were thawed and washed a 
further 4 times by re-suspension and repeated centrifugation 
in assay buffer to remove any possible endogenous inhibitors 
of binding. Aliquots of membrane suspension were incubated 
for 90 minutes at 25°C with 2.5 nM tritiated (2-benzofuranyl)-
2-imidazoline ([3H]2-BFI) in the absence or presence of 
different concentrations of test compound. Test compound 
diluent dimethyl sulfoxide (DMSO) 0.5% final concentration 
was added to total binding samples; non-specific binding was 
determined in the presence of 10 µM 2-(4,5-dihydroimidazol-
2-yl)quinoline hydrochloride (BU224).
Binding to MAO enzymes
Binding assays on monoamine oxidases in rat cerebral cortical 
membranes were conducted according to previously published 
papers.21,22 In summary, for the MAO-A binding assay, triti-
ated N-(2-aminoethyl)-5-(m-fluorophenyl)-4-thiazole carbox-
amide HCl ([3H]Ro 41-1049, 10 nM) was incubated in the 
absence or presence of test compound for 60 minutes at 37°C 
and non specific binding was determined in the presence of 
1 µM clorgyline. For the MAO-B binding assay, incubation 
of [3H]Ro 19-6327(tritiated lazabemide) (15 nM) was car-
ried out for 90 minutes at 22°C and non specific binding was 
determined in the presence of 10 µM (R)-deprenyl.
human recombinant MAO functional assays
MAO-A and MAO-B enzymes were prepared from insect 
cells infected with recombinant baculovirus containing cDNA 
inserts for the human MAO genes. In these experiments, an 
aminopropylether analog of luciferin methyl ester was used 
as a substrate for the MAO reaction. In the first assay step, Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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the enzyme oxidizes the substrate to form luciferin methyl 
ester. In the second step, the methyl ester is hydrolyzed and 
luciferin is oxidized to produce light. Luminescence was 
measured with a luminometer and displayed as relative light 
units (RLU). Half maximal inhibitory concentration (IC50) 
values were calculated by linear regression. Cumulative 
curves analysis (at least 2 independent experiments; log nM 
or log µM concentration of test compound versus % inhibi-
tion) was performed by using the ALLFIT program.
In vivo quantification of endogenous 
norepinephrine tissue levels
Male Wistar rats were orally administered with vehicle or 
CR4056 (20 mg/kg). Two hours later the animals were killed by 
decapitation, and brains or spinal cords were quickly removed 
and transferred in ice-cold artificial cerebrospinal fluid (aCSF) 
of the following composition (mM):125 NaCl, 3 KCl, 1.2 
CaCl2, 1.2 MgSO4, 1 NaH2PO4, 22 NaHCO3, and 10 glucose 
(aerated with 95% O2 and 5% CO2 at 37°C), pH 7.2–7.4. 
Levels of endogenous norepinephrine (NE) were measured in 
parieto-occipital cortices, lumbar spinal cords (L4–L6), and 
plasma samples using a commercial enzymatic immunoassay 
kit (Noradrenaline Research EIA, Nordhorn, Germany).
in vivo models of experimental pain
CR4056 was evaluated in well characterized in vivo   models 
to assess inflammatory and neuropathic pain. Unless 
  otherwise noted, all experimental and control groups con-
tained at least six animals per group. Statistical analysis was 
performed by one-way analysis of variance (ANOVA), with 
P , 0.05 accepted as significant. Inter-group differences 
were assessed by appropriate post hoc comparison tests. 
All data were expressed as the mean ± standard error of the 
mean (SEM).
Complete Freund’s adjuvant (CFA)-induced 
mechanical hyperalgesia
Unilateral inflammation was induced by injecting 100 µL 
of a 50% solution of CFA (Sigma Aldrich, Milan, Italy) in 
physiological saline into the plantar surface of the right hind 
paw of the rat. CFA was injected 24 hours before CR4056 
administration. The rats were fasted overnight before 
experimental use. At the time of the experiment, animals 
were gently restrained, and steadily increasing pressure was 
applied to the dorsal surface of the CFA-treated paw via a 
dome-shaped plastic tip. Paw withdrawal threshold (PWT) 
to mechanical pressure was measured with a Randall-Selitto 
Analgesy-Meter (Ugo Basile, Comerio Varese, Italy).
Capsaicin-induced mechanical hyperalgesia
Rats were fasted overnight before drug administration. A first 
measurement of pain threshold (Randall–Selitto test) was 
undertaken before capsaicin injection. Capsaicin (Sigma 
Aldrich, Milan, Italy) was administered at time t = 0 by the 
intraplantar route in the right hind paw (10 µL of a 1 mg/mL 
Tween 80/saline solution). Sixty minutes later, animals 
were dosed by the oral route with CR4056 (3–30 mg/kg) or 
its vehicle in a volume of 5 mL/kg. A sham control group 
was always present for comparison. In mechanistic studies, 
antagonists were administered 30 minutes after capsaicin and 
15 minutes before CR4056 administration.
Streptozotocin-induced neuropathic  
(diabetic, type I) pain in rats
Diabetes was induced in rats by administration of a single 
dose of streptozotocin (STZ; 75 mg/kg, i.p.). Twelve and 
twenty-four days after STZ injection, the presence of diabetes 
was confirmed by measuring blood glucose concentrations. 
Animals with values lower than 250 mg/dL were excluded 
from the studies. CR4056 was orally administered at doses 
of 6, 20, or 60 mg/kg four weeks after the STZ injection. 
Paw withdrawal threshold (PWT) to mechanical pressure 
was measured with a Randall–Selitto Analgesy-Meter (Ugo 
Basile, Comerio Varese, Italy).
Acid-induced muscle allodynia in rats
Male Wistar rats were brought to the behavioral testing 
room 1 hour before the test to acclimatize them to the testing 
environment. The right gastrocnemius muscle was injected 
with 150 µL of pH = 4 preservative-free sterile saline. 
Five days later (d5), the same gastrocnemius muscle was 
  re-injected using an identical injection protocol. As a con-
trol for the injection procedure, a separate group of animals 
were injected with sterile saline. Ipsilateral and contralateral 
paw withdrawal thresholds were measured in response to 
mechanical stimuli on days 0 (baseline – 0d), 5 (5d) and 
24 hours after the second acid injection (6d). Nociceptive 
thresholds, expressed in grams (g), were measured using 
a Dynamic Plantar Aesthesiometer (Ugo Basile, Comerio 
Varese, Italy) by applying increasing pressure to the right 
and left hind paw until the rat withdrew the paw.23 A maximal 
cut-off of 50 g was used to prevent tissue   damage. The 
threshold was tested three times for each paw and the 
mean value was calculated. CR4056 was administered as 
oral suspension at doses of 6, 20 and 60 mg/kg in com-
parison to intraperitoneal gabapentin (30 mg/kg) dissolved 
in saline. Mechanical withdrawal thresholds of both hind Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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paws were measured 1 hour and 30 minutes after CR4056 
and gabapentin   injection respectively. One-way analysis 
of variance (ANOVA)   followed by post hoc analysis for 
multiple comparisons were used to evaluate the differences 
between groups for each pharmacological treatment: a paired 
t-test was performed to evaluate the differences between 
the mechanical withdrawal thresholds before the first acidic 
saline injection (0d) and 24 hours after the second injection 
(6d), before pharmacological treatments.
Motor function assays
Locomotor activity was measured in an open field arena by 
using an overhead video camera coupled to a microcomputer 
by an image analyzer (EthoVision, Noldus Information 
  Technology, Sterling, VA) used to track movement of rats 
in the arena. A remote switch was used to start and stop 
  tracking. For the rotarod assay, rats were allowed a 30 minute 
acclimatization period in the testing room and then placed 
on a 9 cm diameter rod, which increased in speed from 
0 to 20 rpm over a 60 second period. The time required for the 
rat to fall from the rod was recorded, with a maximum score 
of 60 seconds. Each rat was given three training sessions.
chemicals
The following chemicals were used: capsaicin, naloxone, 
efaroxan, yohimbine, prazosin, idazoxan, streptozotocin, 
clonidine, clorgyline, (R)-deprenyl, human recombinant 
MAO-A and MAO-B (Sigma Aldrich, Milan, Italy); 2-(2-
benzofuranyl)-2-imidazoline (2-BFI) and 2-(4,5-dihydroim-
idazol-2-yl)quinoline hydrochloride (BU-224) (Tocris 
Cookson, Bristol, UK). [3H]-2-BFI, [3H]Ro 41-1049 and 
[3H]Ro 19-6327 (GE Healthcare, Milan, Italy); MAO-Glo 
assay kit (Promega, Madison, WI). CR4056 (2-phenyl-6-(1H-
imidazol-1yl)quinazoline) was synthesized by the Medicinal 
Chemistry Department of Rottapharm. For in vitro assays 
CR4056 stock solutions (10 mM) in DMSO were prepared, 
diluted in the corresponding assay buffer and used the same 
day. For in vivo oral administration, CR4056 was suspended 
in 0.5% methyl cellulose (MC) in 5 mL/kg injection volume; 
all the other drugs were dissolved in 0.9% normal saline for 
intraperitoneal (i.p.) or subcutaneous (s.c) administration.
Results
Receptor characterization panel
A receptor characterization panel including adrenergic, sero-
tonergic, dopaminergic, opioid, cholinergic (muscarinic and 
nicotinic), and sigma receptors, as well as some amino acid 
receptor types (gamma-aminobutyric acid [GABA], glycine, 
glutamate) was performed. Percent inhibition of specific 
binding at the concentration tested (10 µM) is reported in 
Table S1 (supplementary data). Moreover, a limited enzyme 
characterization panel including cycooxygenase-2 (COX2), 
inducible NO synthase (iNOS), TNF-α converting enzyme, 
carbonic anhydrase II, phosphoinositide 3-kinases (PI 3-Kβ, 
PI 3-Kγ, PI 3-Kδ), catechol-O-methyl transferase (COMT) 
and human mTOR kinase was performed (not shown). 
CR4056 was inactive in all assays but inhibited the affinity 
for I2 imidazoline receptors and monoamine oxidases A 
(MAO-A) by more than 90%.
Binding to imidazoline I2 receptors
The purpose of this study was to investigate the effects of 
CR4056 in a receptor binding assay selective for the I2 recep-
tor subtype. We used rat whole-brain membranes labeled with 
the specific radioligand [3H]2-BFI. Matching experiments with 
various reference compounds were run for comparison. Table 
S2 (supplementary data) summarizes the effects of CR4056 and 
reference compounds. CR4056 inhibited [3H]2-BFI binding 
with an affinity value (IC50) of 596 ± 76 nM (n = 3). Affinities 
of reference compounds were in line with published data.
Binding and functional activity assays  
on MAO
The effect of CR4056 was studied in receptor binding assays 
to evaluate its affinity for MAO-A and MAO-B sites in rat 
cerebral membranes. The refeDrence agents were tested 
concurrently with the test compound in order to assess the 
assay suitability. CR4056 inhibited MAO-A specific binding 
with an IC50 of 358 ± 12 nM (n = 3). Inhibition of MAO-B 
specific binding was achieved at concentrations two orders 
of magnitude higher. Binding assay results on rat cerebral 
native MAO and functional activity data, obtained on human 
recombinant enzymes, were shown to be consistent with each 
other. Table S3 (supplementary data) summarizes the effects 
of CR4056 and reference compounds on the activity of mono-
amine oxidases. CR4056 selectively inhibited the enzymatic 
activity of MAO-A, with an IC50 value of 202.7 ± 10.3 nM 
(n = 3). As for the binding study, CR4056 was about 100 
times less active as an inhibitor of MAO-B activity. The 
activity and selectivity of the reference compounds were in 
agreement with published data.
in vivo effects on endogenous 
norepinephrine (NE) levels
Two hours after a single oral dose of 20 mg/kg CR4056, endog-
enous NE levels increased by 68.2% ± 14.1% (P , 0.05 versus Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Figure 1 Effects of acute and sub-chronic oral treatment (once daily for 4 days) with CR4056 on endogenous norepinephrine (NE) levels in rat parieto-occipital cortex, 
lumbar spinal cord (L4–L6) and plasma. 
Notes: Data represent the mean ne levels expressed as pg/sample ± SEM (n = 5). *P , 0.05 versus basal NE levels found in rats administered with vehicle (Student’s t-test).
vehicle; Student’s t-test) in the parieto-occipital cortex. The 
effect of CR4056 at the spinal cord level was not statistically 
significant, but there was a clear tendency for NE levels to 
increase (Figure 1). No effect was found in plasma samples. 
Sub-chronic (four days) oral treatment with 20 mg/kg CR4056 
once daily, significantly increased NE levels both in the cere-
bral cortex (63.1% ± 4.2%; P , 0.05 versus vehicle; Student’s 
t-test) and in the lumbar spinal cord (51.3% ± 6.7%; P , 0.05 
versus vehicle; Student’s t-test).
CFA-induced inflammatory pain in rats
Male Wistar rats were injected into the right hind footpad 
with 50 µg of Mycobacterium tuberculosis in 100 µL vehicle 
(CFA). Twenty-four hours later, CR4056 (6, 20, or 60 mg/kg) Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
116
Ferrari et al
140
−24 h
CFA Drug administration (OS)
Sham
Vehicle
10 mg/kg piroxicam
6 mg/kg CR4056
20 mg/kg CR4056
60 mg/kg CR4056
06 0 120 1802 40 3003 60 Time (min)
M
e
c
h
a
n
i
c
a
l
 
t
h
r
e
s
h
o
l
d
 
(
g
)
160
180
200
220
240
260
280
300
320
340
Figure 2 Antinociceptive effects of CR4056 on CFA-induced inflammatory pain in rats (Randall-Selitto test). CR4056 was orally administered 24 hours after a CFA injection in the 
right hind paw of the rats. Piroxicam (10 mg/kg; oral) was used as a positive control. 
Notes: Data represent the mean withdrawal threshold expressed in grams ± SEM (n = 6 per group).
or piroxicam (10 mg/kg) was administered by the oral route 
and the response to noxious mechanical stimulation was 
assessed by measuring the paw withdrawal threshold (PWT) 
(Figure 2). In this experimental model of inflammatory pain, 
CR4056 dose-dependently reduced mechanical hyperalgesia 
(effective dose [ED50] = 5.8 mg/kg) (Kruskal–Wallis one way 
ANOVA: H[5, 36] = 27.23, P , 0.001). A complete reversion 
of CFA-induced hyperalgesia was achieved at the calculated 
ED100 dose of 22.3 mg/kg.
Capsaicin-induced neurogenic/
inflammatory pain in rats
This experimental paradigm has been thoroughly investigated 
to understand the pharmacology of CR4056 analgesic proper-
ties. The effect of CR4056 on capsaicin-induced mechanical 
hyperalgesia was examined in male Wistar rats. Capsaicin 
(0.1%) or its vehicle (saline containing 1.5% Tween 80 and 
1.5% ethanol) was injected subcutaneously into the plantar hind 
paw. The total injected volume was 10 µL. One hour after the 
challenge, animals received oral CR4056 (3, 10, or 30 mg/kg), 
piroxicam (10 mg/kg) or vehicle. Paw withdrawal threshold was 
measured 1 hour before capsaicin treatment, immediately before 
the administration of test compounds and 1 and 2 hours later.
Baseline withdrawal threshold to mechanical pressure 
was about 230 g. Sixty minutes after capsaicin injection, 
withdrawal threshold decreased to 162 ± 15 g (P , 0.01 
  versus baseline). CR4056 (10 mg/kg) and piroxicam 
(10 mg/kg) significantly reversed the decrease in withdrawal 
threshold caused by capsaicin (P , 0.001 versus vehicle; 
  Bonferroni t-test) (Figure 3). The highest tested dose of 
CR4056 (30 mg/kg) completely reversed the effect of cap-
saicin, increasing PWT to 239 ± 12 g (P , 0.001 versus 
vehicle; Bonferroni t-test) after 1 hour.
In vitro data clearly demonstrated a selective interaction 
of CR4056 with imidazoline I2 receptors. We therefore tried 
to better characterize the analgesic effect of the compound 
by administering different antagonists of imidazoline and/
or adrenergic receptors to capsaicin-treated rats 15 min-
utes before a full analgesic dose of CR4056 (30 mg/kg). 
Moreover, because high doses of CR4056 could mimic the 
effect of some opioid agonists (ie, morphine) and cause 
hypoalgesia, we also tested the hypothesis of an indirect 
in vivo modulation of the opioidergic system by CR4056. 
For this purpose, capsaicin-treated rats were given naloxone, 
a µ-opioid antagonist, 15 minutes before CR4056 adminis-
tration. Efaroxan (a non-selective antagonist of imidazoline 
I1 and adrenergic α2 receptors), yohimbine (a selective α2 
antagonist) and prazosin (a selective α1 antagonist) did 
not influence the effect of CR4056 on capsaicin-induced 
mechanical hyperalgesia (Figure 4, Panel A). Conversely, Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Figure 3 Capsaicin-induced neurogenic/inflammatory pain in rats: effect of increasing oral doses of CR4056 (Randall–Selitto test). CR4056 (range: 3–30 mg/kg) dose-
dependently reversed the mechanical hyperalgesia induced by an intraplantar injection of capsaicin (F[5, 36] = 27.57, P , 0.001). Piroxicam (10 mg/kg; oral) was used as a 
positive control. 
Notes: Data represent the mean withdrawal threshold expressed in grams ± SEM (n = 6 per group).
idazoxan (3 mg/kg; a non-selective antagonist of imidazoline 
I2 and adrenergic α2 receptors) greatly reduced the analgesic 
action of CR4056 (74.1% ± 12.7%, P , 0.001 versus group 
of animals treated with 30 mg/kg CR4056 only). Naloxone 
antagonized the slight hypoalgesic effect previously reported 
but not the analgesic effect induced by CR4056. In a con-
firmatory experiment, idazoxan (0.3, 1, and 3 mg/kg i.p.) 
dose-dependently inhibited the analgesic effect of CR4056 
by decreasing PWT (increased hyperalgesia) in capsaicin-
treated rats (Figure 4, Panel B) (Kruskal–Wallis one way   
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Figure 4 Capsaicin-induced neurogenic/inflammatory pain in rats (Randall–Selitto test). Panel A: effects of different receptor antagonists on the analgesic activity induced by 
30 mg/kg oral CR4056.
Notes: Data represent the mean percent area under the curve (AUC) ± SEM in the absence or presence of the antagonist (n = 6 per group). *P , 0.05 versus CR4056 
treated animals (Holm–Sidak test). Panel B: dose-dependent effect of idazoxan on the analgesic activity induced by 30 mg/kg oral CR4056. Data represent the mean 
withdrawal threshold expressed in grams ± SEM (n = 6 per group).Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Figure  5  Isobologram  for  the  effects  of  CR4056  and  morphine,  alone  or  in 
combination, in capsaicin-induced neurogenic/inflammatory pain in rats. Filled circle 
corresponds to the experimental co-treatment ED50 with 95% confidence limits; 
open square corresponds to the experimental eD50 for morphine alone, and open 
diamond corresponds to the experimental ED50 for CR4056 alone.
ANOVA: H [5, 71] = 48.50, P , 0.001). The maximal inhi-
bition observed in the presence of 3 mg/kg idazoxan was 
76.1% ± 9.5%, consistent with the previous study.
We also examined the effects of co-administered 
  morphine and CR4056 and determined the type of interac-
tion between the two treatments. Morphine (0.03–3 mg/kg, 
subcutaneously), CR4056 (0.3–30 mg/kg, orally) and their 
combination produced a significant, dose-dependent anti-
hyperalgesic effect in capsaicin-injected rats. Isobolographic 
analysis revealed a significant synergistic interaction between 
morphine and CR4056 (Figure 5). When these agents were 
combined, the doses needed to reach the median effective 
dose were about 4-fold lower than those seen after admin-
istration of each drug alone (ED50: 0.98 versus 4.13 mg/kg 
for CR4056, 0.097 versus 0.36 mg/kg for morphine).
Streptozotocin-induced neuropathic 
(diabetic, type I) pain in rats
CR4056 dose-dependently decreased STZ-induced dia-
betic pain in rats (F[4, 35] = 31.27, P , 0.001) (Figure 6). 
Oral treatment at a dose of 60 mg/kg completely reversed 
mechanical hyperalgesia within 30 minutes. Moreover, 
AUC analysis (0–6 hours) showed that 60 mg/kg CR4056 
decreased by 84% the total STZ-induced hyperalgesic effect 
(P , 0.001 versus vehicle, Bonferroni t-test). The µ-opioid 
receptor agonist morphine (20 mg/kg, s.c.) completely 
reversed the hyperalgesia at 30 and 90 minutes after treat-
ment, with some degree of hypoalgesia. However, PWT at 
6 hours in morphine-treated rats was not different from that 
in untreated diabetic rats. Conversely, the analgesic effect of 
CR4056 lasted longer: a 60 mg/kg dose significantly reduced 
mechanical hyperalgesia by 58% at 6 hours post-dosing 
(P , 0.05 versus vehicle, Bonferroni t-test).
Acid-induced muscle allodynia in rats
The acidic saline animal model of pain is thought to mimic 
human chronic pain syndromes such as fibromyalgia. 
Repeated intramuscular injections of acidic saline is a 
model of non-inflammatory pain characterized by bilateral 
long-lasting allodynia of the paw, which is believed to be 
centrally mediated.24
CR4056 significantly increased the mechanical withdrawal 
thresholds of both ipsilateral (F[4, 30] = 19.97, P , 0.001) 
and contralateral (F[4, 30] = 31.58, P , 0.001) hind paws 
compared with vehicle control (Figure 7). A pairwise multiple 
comparison procedure (Holm–Sidak method) further evi-
denced that the anti-nociceptive effects of 6 mg/kg CR4056 and 
30 mg/kg gabapentin were similar. CR4056 20 and 60 mg/kg 
completely reversed acidic saline induced allodynia. No statis-
tically significant difference was detected between the groups 
treated with CR4056 at 20 and 60 mg/kg.
Motor function: rotarod and open  
field tests
International requirements for central nervous system (CNS) 
safety pharmacology include assessment of motor coordination 
and locomotor activity. The rotarod test provides an estimation 
of the animal’s level of neuromuscular coordination.
Oral administration of CR4056 in a dose range of 
3–30 mg/kg did not cause a deterioration of animals’ per-
formance in a rotarod test. In addition, an open field test was 
used to measure locomotor activity. There were no statistical 
differences in locomotor activity levels after CR4056 treatment 
(3–30 mg/kg by oral administration) one hour after administra-
tion. Indeed, we repeated the test six hours after CR4056 admin-
istration and after four days of treatment (once daily) without 
any noticeable differences in the motor behavioral pattern.
Discussion
CR4056 is a new ligand of the imidazoline-2 sites (I2R) with 
efficacy in several models of pain. In particular CR4056, 
administered by the oral route, almost invariably showed a 
complete reversion of hyperalgesia induced by local (CFA) 
or neurogenic (capsaicin) inflammation, and by experimental 
neuropathies (diabetes and acid-induced muscle allodynia). 
In all of these paradigms, doses of CR4056 below 20 mg/kg Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Figure 6 Streptozotocin (STZ)-induced neuropathic (diabetic, type I) pain in rats: effects of increasing oral doses of CR4056 (Randall–Selitto test). Diabetes was induced 
in rats by administration of a single dose of STZ (i.p.). CR4056 was orally administered four weeks after the STZ injection. Morphine (20 mg/kg; s.c.), was used as a 
positive control. 
Note: Data represent the mean withdrawal threshold expressed in grams ± SEM (n = 7 per group).
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Figure 7 Antiallodynic effects of CR4056 in the acid-induced muscle allodynia model in rats (Dynamic Plantar Aesthesiometer; Ugo Basile, VA, Italy). Right gastrocnemius 
muscle was injected with acidic saline (pH = 4). Five days later (d5), the same gastrocnemius muscle was re-injected using an identical injection protocol. As a control for the 
injection procedure, a separate group of animals were injected with sterile saline. Six days after the first acidic saline injection, CR4056 was orally administered to rats two 
hours before testing. Gabapentin (GBP) (30 mg/kg; i.p.) was used as positive control. 
Notes: Data represent the mean withdrawal threshold expressed in grams (n = 6 per group). Standard errors of the mean (SEM) have been omitted for clarity of 
presentation (available as supplementary data in Table S4). 
Abbreviations: DX, right paw; sX, left paw.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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were highly effective against the exaggerated pain sensation, 
while higher doses proved to be, as in the case of opiates, 
decidedly hypoalgesic.
However, as shown in vitro by a broad binding screen-
ing panel, CR4056 does not interact directly with any of 
the known opioid receptors. In the last few years Cheng 
et al25,26 significantly contributed to the explanation as to 
why a modulator of imidazoline-2 receptors should mimic 
the effect of some opioid receptor ligands. In fact, they 
showed that agmatine, the endogenous ligand of imidazo-
line receptors, increased beta-endorphin secretion in the 
rat adrenal medulla and this effect was blocked by the I2R 
putative antagonists BU-224 and amiloride. This peripheral 
beta-endorphin increase will possibly be additive to the well 
described central effect induced by I2 ligands27 on the firing 
rate of locus coeruleus neurons, where there is a cross-link 
between I2 sites and the opioid system. This interaction leads 
to an attenuation of both the hyperactivity of locus coeruleus 
neurons during opiate withdrawal and the development of 
tolerance to morphine when agmatine or 2-BFI is chronically 
administered.18
In this paper, the pharmacology of the analgesic activity 
of CR4056 was examined in vivo using the simple model of 
capsaicin-induced neurogenic pain. In this model, it has been 
clearly demonstrated that, while the concomitant treatment 
with α1, α2, or I1 antagonists did not affect the efficacy of 
CR4056, treatment with the nonselective I2 antagonist ida-
zoxan dose-dependently abrogated the effect of a fully active 
dose of CR4056, suggesting that the binding with the I2 site is 
a primary requirement for its efficacy. Interestingly, naloxone, 
an opiate antagonist, was only able to dampen the hypoalgesic 
effect of CR4056, but not its analgesic properties, suggesting 
that the hypoalgesic component could be due to the release of 
endogenous endorphins, as observed with other I2 ligands.26
In this respect, the capsaicin model was also useful to 
evaluate a possible synergy between morphine and CR4056. 
Morphine is the most commonly used opioid for the treatment 
of severe pain, but adverse effects, including nausea and respi-
ratory depression, limit its use. Combination therapy is a valid 
approach in pain management because optimal analgesia can 
be reached at lower doses of each drug than those required in 
monotherapy. Generally, if different mechanisms jointly con-
tribute to pain control, a synergistic interaction is considered 
likely. Such combination may decrease the necessary dose of 
individual drugs, thereby increasing the maximum analgesic 
effect with a decreased incidence of adverse effects. Conversely, 
if the mechanisms of action of one drug are involved in those 
of another drug, a synergistic interaction is not expected. The 
combination of CR4056 with morphine has been found to be 
clearly synergic, being about three- to four-fold more effective 
than predicted on the basis of a simple additive effect.
Potential interactions with other pain modulatory 
systems, such as the cannabinoid28,29 pathway, have been 
proposed in the last few years to explain the efficacy of 
imidazoline site ligands in preclinical models. For instance, 
Aggarwal et al29 found a synergistic effect of agmatine and 
WIN 55212-2 (a CB1 cannabinoid agonist) in the hot-plate 
assay of thermal nociception in rats. They also found that 
the mixed I2/α2 antagonist idazoxan, but not the selective 
α2 antagonist yohimbine, dose-dependently antagonizes the 
enhanced response-latency produced by co-administration 
of agmatine and WIN 55212-2. In exploratory experiments 
we tested whether a commercially available CB1 antagonist 
(AM-251) could antagonize the analgesic effect of CR4056 
in the rat model of capsaicin-induced neurogenic pain. 
Unlike idazoxan, AM-251 had no effect under the experi-
mental condition chosen (data not shown), suggesting that 
the cannabinoid pathway is not involved in the mechanisms 
underlying CR4056-induced analgesia.
Another important issue to consider in the evaluation of 
CR4056 mechanism of action is its effect on monoamine oxi-
dase A. Although in the literature there is still no consensus 
about the nature of I2-MAO interaction,6,7,30 most I2R ligands 
are reported to inhibit the activity of MAO, thereby inducing 
a net increase of endogenous catecholamines available at 
synaptic level. CR4056 was found to selectively inhibit the 
activity of human recombinant MAO-A with sub-micromolar 
affinity and, when administered orally to rats, to increase the 
norepinephrine tissue levels both in the cerebral cortex and in 
the lumbar spinal cord. The role of norepinephrine in control-
ling spinal and supraspinal pain modulatory effects is well 
documented by both preclinical and clinical data.31–34 In par-
ticular, as a general mechanism of the noradrenergic theory of 
pain, peripheral nociceptive stimuli induce the activation of 
noradrenergic projections from higher centres including the 
locus coeruleus to the spinal cord, resulting in antinocicep-
tion and inhibition of spinal nociceptive neurons. This story 
becomes complicated due to some findings showing that 
noradrenergic neurons of the locus coeruleus do not always 
induce pain inhibition, and can also generate paradoxical 
facilitation, probably mediated by synaptic afferents to the 
rostral ventral medulla (RVM), a well known pain facili-
tatory centre.35–37 However, current therapeutic guidelines 
clearly state that drugs able to enhance the central synaptic 
levels of norepinephrine (ie, TCAs and/or the newer mixed 
norepinephrine/serotonin re-uptake inhibitors –[SNRIs]) are Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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one of the first line treatments recommended for the manage-
ment of neuropathic pain conditions.20,38,39 Moreover, recent 
findings show that metabolism of catecholamines by sensory 
neurons contributes to peripheral neuropathies by producing 
neurotoxic metabolites, suggesting that MAO-A inhibitors 
devoid of central adverse effects could be useful for the 
treatment of neuropathic pain.40 This could be the case for 
functional MAO-A inhibitors, such as CR4056, modulating 
the enzyme activity through accessory sites present in discrete 
populations of enzymes.4,5
During the pre-clinical development path enabling 
CR4056 to enter into human clinical studies, safety pharma-
cology findings were consistent with the activity of CR4056 
on the catecholamine system. At supra-pharmacological 
doses in the conscious dog, CR4056 induced slight hyper-
tensive effects associated with tachycardia. Consistently, 
tachypnea associated with a respiratory stimulant effect 
was observed in the conscious rat. Interestingly, all these 
effects on cardio-respiratory functions can be produced by 
excitation of afferent cardiac sympathetic nerve fibers and 
are functionally opposite to what is generally observed after 
administration of analgesic opiates. It is well known that 
morphine administration in rats and dogs decreases heart 
rate, blood pressure, and cardiac output.41 Additionally, all 
opiates acting at the µ receptor induce a marked respiratory 
depression that complicates their clinical administration and 
that is potentially life threatening in the case of opiate over-
dose.42 This could be relevant in view of the demonstrated 
synergy between morphine and CR4056. On the other hand, 
the absence of respiratory depression, hypotension, and 
bradycardia in animals treated with CR4056 rules out the 
possibility that this compound directly activates central α2 
receptors, whose stimulation by drugs like clonidine, in case 
of overdosage, induces hypotension, bradycardia, sedation, 
miosis, and respiratory depression.43
Besides the above described effects, when tested in the 
pharmacological/toxicological range in rats, CR4056 induced 
a dose-dependent diuretic effect. Notably, the diuretic effect 
of CR4056 is shared by several imidazoline receptor ligands 
such as the diuretic amiloride, a putative selective ligand for 
the I2A subtype,44,45 and the anti-hypertensive drug moxoni-
dine, which is considered to be selective for imidazoline I1 
receptors even though its diuretic activity is blocked by the 
I2/α2 antagonist idazoxan.46
Conclusion
CR4056 is a very effective analgesic compound active in 
several preclinical models relevant for important human 
pathologies including fibromyalgia and diabetes-induced 
neuropathy. CR4056 has now completed preclinical devel-
opment and a phase I safety study in humans has now been 
designed to finally develop the compound as a first in class 
I2 ligand in chronic and neuropathic pain conditions.
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Table S1 CR4056 receptor characterization panel
Receptor Labeled ligand Tissue/species Reference agents  
(IC50, nM)
10 µM CR4056   
(% effect)
5-HT1A [3H]8-OH-DPAT hippocampus/rat 8-OH-DPAT, 1.9 
5-HT, 11.4
in
5-HT2A [3H]Ketanserin Prefrontal cerebral cortex/rat Ketanserin, 3.1
5-HT, 8.2
in
5-HT3 [3H]BRL 43,694 Hippocampus-cortex/rat granisetron, 0.44
5-HT, 328
28% ISB
5-HT uptake [3H]Paroxetine Whole brain/rat 6-nitro-Quipazine, 0.29
5-HT, 2400
in
D1 [3H]SCH 23,693 striata nuclei/rat SCH 23,693, 0.97
DA, 5100
19% ISB
D2 [3H]Spiperone striata nuclei/rat spiperone, 2.2
DA, 330
25% ISB
Alpha 1 (A+B) [3H]Prazosin Whole brain/rat Prazosin, 2.4
5-Me-Urapidil, 38
in
Alpha 2 [3H]Yohimbine cerebral cortex/rat Yohimbine, 18.7
clonidine, 40.1
in
ne uptake [3H]Nisoxetine cerebral cortex/rat nisoxetine, 1.1
Desipramine, 1.5
in
i1 [3H]Clonidine (+10 µM  
RX 821002)
Adrenal medulla glands/ 
bovine
Rilmenidine, 130 23% ISB
i2 [3H]Idazoxan (+1 µM  
yohimbine)
cerebral cortex/rat Idazoxan, 6.5
clonidine, 42.1
66% ISB
i2 [3H]2-BFI Whole brain/rat 2-BFI, 5.8
Idazoxan, 11.4
clonidine, 8320
92% ISB
MAO-A [3H]Ro 41-1049 cerebral cortex/rat clorgyline, 2.1
Ro 41-1049, 74.3
97% ISB
MAO-B [3H]Ro 19-6327 cerebral cortex/rat (R)-Deprenyl, 17
Ro 16-6491, 25
35% ISB
MOP (Opiate µ) [3H]DAMGO Brain/guinea pig naloxone, 1.55
DAMgO, 1.33
in
DOP (Opiate δ) [3H]Naltrindole Brain/guinea pig Naloxone, 264
naltrindole, 1.25
in
KOP (Opiate κ) [3H]U-69,593 Brain/guinea pig naloxone, 54
Tifluadom, 0.5
in
NOP (ORL1) [3H]Nociceptin human recombinant  
(HEK-293 cells)
nociceptin, 1.3 in
Muscarinic [3H]QNB cerebral cortex/rat Atropine, 2.5
scopolamine, 5
in
Nicotinic (α4β2) [3H]Epibatidine Whole brain/rat nicotine, 312 in
Sigma (σ1 + σ2) [3H]DTG Whole brain/rat haloperidol, 97 18% ISB
nMDA/channel site [3H]MK-801 cerebral cortex/rat MK-801, 8.2
Memantine, 1300
in
mGLU II [3H]LY341495 cerebral cortex/rat LY341495, 8.6
L-glutamic acid, 166
in
CCK1 [125I]Cholecystokinin 26-33 
(sulfated)
Pancreas/rat CCK-8, 1.4 nM
Devazepide, 7.9 nM
21% ISB
CCK2 [125I]Cholecystokinin 26-33 
(sulfated)
cerebral cortex/guinea pig CCK-8, 0.3 nM
YM 022, 0.17 nM
16% ISB
Glycine (strychnine- 
sensitive)
[3H]Strychnine spinal cord/rat strychnine, 10
glycine, 13000
19% ISB
GABA-A (muscimol site) [3H]Muscimol cerebral cortex/rat Muscimol, 15 26% ISB
GABA-A (channel-site) [35S]TBPS cerebral cortex/rat Picrotoxinin, 270 in
GABA-B (1b) [3H]CGP 54626 human recombinant  
(HEK-293 cells)
CGP 54626, 6.4
Baclofen, 22800
in
(Continued)
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Table S1 (Continued)
Receptor Labeled ligand Tissue/species Reference agents  
(IC50, nM)
10 µM CR4056   
(% effect)
BDZ (central) [3H]Flunitrazepam cerebral cortex/rat Diazepam, 14 21% ISB
VIP1 (VPAC1) [125I]VIP human recombinant  
(CHO cells)
ViP, 0.094
PACAP1-27, 1.8
in
VIP2 (VPAC2) [125I]VIP human recombinant  
(CHO cells)
VIP, 1.6
PACAP1-27, 4.2
in
Vanilloid [3H]Resiniferatoxin Wistar Rat spinal cord Resiniferatoxin in
PPAR gamma [3H]Rosiglitazone human recombinant
(E. coli)
Rosiglitazone, 20 in
Alpha2delta (gabapentin site) [3H] Gabapentin Wistar Rat brain cortex gabapentin in
Abbreviations: IN, inactive; ISB, inhibition of specific binding.
Table S3 Effects of CR4056 and reference compounds on the 
enzymatic activity of human recombinant MAO-A and MAO-B
Compound IC50, nM
MAO-A MAO-B
CR4056 202.7 ± 10.3 (n = 3) .10000 (n = 3)
clorgyline 19.5 ± 1.1 (n = 3) 45300 ± 3895 (n = 2)
Deprenyl 19100 ± 1026 (n = 2) 347 ± 32 (n = 2)
2-BFI 10 µM = −57% (n = 3) 10 µM = −61% (n = 3)
Notes: MAO-A and MAO-B enzymes were prepared from insect cells infected with 
recombinant baculovirus containing cDnA inserts for the human MAO genes. ic50 
values of CR4056 and reference compounds were calculated by linear regression. 
Cumulative curves analysis (at least 2 independent experiments; log nM or log µM 
concentration of test compound versus % inhibition) was performed by using the 
ALLFiT program. Values are reported as mean ± seM.
Abbreviation: n, number of independent experiments.
Table S2 Effects of CR4056 and reference compounds on [3H]2-BFI 
binding to the imidazoline I2 receptor in rat cerebral membranes
Compound IC50, nM
CR4056 596 ± 76 (n = 3)
2-BFI 10.3 ± 2.4 (n = 3)
BU224 8.7 ± 2.1(n = 2)
Idazoxan 11.4 ± 3.4 (n = 3)
clonidine 8320 ± 258 (n = 2)
Notes:  Whole  brain  membranes  from  male  Wistar  rats  were  incubated  for 
90 minutes at 25°C with 2.5 nM [3H]2-BFI in the absence or presence of different 
concentrations  of  test  compound.  Non-specific  binding  was  determined  in  the 
presence  of  10  µM  BU224.  Cumulative  curves  analysis  (at  least  2  independent 
experiments; log nM or log µM concentration of test compound versus % inhibition) 
was performed by using the ALLFiT program. Values are reported as mean ± seM. 
Abbreviation: n, number of independent experiments.Journal of Pain Research
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Preclinical evaluation of CR4056 analgesic efficacy
Table S4 Acid-induced muscle allodynia in rats
Time (day) Mechanical threshold (grams) ± SEM
Right paw (DX)
0 32.1 ± 0.9 32.5 ± 0.6 32.6 ± 0.7 31.0 ± 0.5 32.7 ± 0.7 32.9 ± 0.6
saline ph = 7 saline ph = 4 saline ph = 4 saline ph = 4 saline ph = 4 saline ph = 4
5 33.0 ± 1.0 25.5 ± 0.8 26.4 ± 0.7 24.7 ± 1.4 27.3 ± 0.4 25.5 ± 1.5
saline ph = 7 saline ph = 4 saline ph = 4 saline ph = 4 saline ph = 4 saline ph = 4
6 32.3 ± 0.3 21.0 ± 1.0a 22.0 ± 1.1a 20.6 ± 1.2a 23.6 ± 1.1a 23.6 ± 1.1a
Vehicle (sham) Vehicle gabapentin 
30 mg/kg; iP
CR4056 
6 mg/kg; OS
CR4056 
20 mg/kg; Os
CR4056 
60 mg/kg; OS
6 33.1 ± 0.5 20.4 ± 1.2a 30.1 ± 0.9b 28.3 ± 1.9b 38.4 ± 1.7b 37.4 ± 2.1b
Left paw (SX)
0 32.6 ± 0.7 31.9 ± 0.5 32.8 ± 0.6 32.2 ± 0.7 32.5 ± 0.5 31.9 ± 0.4
saline ph = 7 saline ph = 4 saline ph = 4 saline ph = 4 saline ph = 4 saline ph = 4
5 32.5 ± 0.6 27.4 ± 0.9 26.1 ± 1.1 24.5 ± 0.9 26.6 ± 0.8 27.9 ± 0.6
saline ph = 7 saline ph = 4 saline ph = 4 saline ph = 4 saline ph = 4 saline ph = 4
6 32.3 ± 0.6 21.7 ± 0.8a 22.4 ± 0.9a 21.3 ± 0.4a 23.9 ± 1.2a 25.0 ± 0.9a
Vehicle (sham) Vehicle gabapentin 
30 mg/kg; iP
CR4056 
6 mg/kg; OS
CR4056 
20 mg/kg; Os
CR4056 
60 mg/kg; OS
6 32.4 ± 0.4 20.2 ± 0.9a 31.4 ± 2.0b 27.9 ± 1.1b 37.1 ± 0.8b 39.2 ± 1.6a,b
Notes: Antiallodynic effects of CR4056 in the acid-induced muscle allodynia model in rats (electronic Von Frey test). The right gastrocnemius muscle was injected with acidic 
saline (pH = 4). Five days later, the same gastrocnemius muscle was re-injected using an identical injection protocol. As a control for the injection procedure, a separate 
group of animals were injected with sterile saline. Six days after the first acidic saline injection, CR4056 was orally administered to rats two hours before testing. Gabapentin 
(GBP) (30 mg/kg; intraperitoneal) was used as positive control. Data represent the mean thresholds (±SEM) expressed in grams (n = 6 per group). aP , 0.05 versus vehicle 
treated (sham) animals (Holm–Sidak test); bP , 0.05 versus vehicle treated animals (Holm–Sidak test).